Shares of Tempus AI, Inc. (NASDAQ:TEM) climbed around 12% on Monday after the precision medicine and data analytics company revealed it had reached a new milestone in total contract value, surpassing $1.1 billion as of December 31, 2025.
The Chicago-based group also released preliminary, unaudited figures showing full-year 2025 data and application revenue of roughly $316 million, representing year-on-year growth of about 31%. Performance was even stronger in the Insights segment, which focuses on data licensing, with revenue up 38% compared with the prior year.
During 2025, Tempus entered into data agreements with more than 70 customers. These included major pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer and Novartis, alongside biotechnology groups including Incyte and Servier.
Tempus reported a net revenue retention rate of approximately 126% for the year, reflecting significant expansion within its existing customer base despite the company’s growing scale.
“2025 was a record year for our Data and applications business – both from a revenue and TCV perspective,” said Jim Rogers, Chief Financial Officer at Tempus. “Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”
The company cautioned that the figures disclosed are preliminary and unaudited. Tempus said it expects to release its full fourth-quarter and full-year 2025 financial results during its earnings call scheduled for February 2026.